All News
ICYMI: Update on Axial SpA at EULAR 2022
This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference.
Read Article
Baricitinib fails in 2 phase 3 lupus trials, BRAVE I & II #EULAR2022 abtr POS 0190 https://t.co/44e5NX4V1V
Dr. John Cush RheumNow ( View Tweet)
Adults with JIA: It ain’t all child’s play
https://t.co/z3xDjKH2ru https://t.co/9DDGYdpMSr
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast up—“What Worries You, Masters You”
We review recent news, regulatory and guideline updates from the past week. Studies on MTX use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.
https://t.co/jRaLCQAt9K https://t.co/opa22JqU41
Links:
Dr. John Cush RheumNow ( View Tweet)
Exercise and fibromyalgia? Metanalysis of 18 studies & 1184 pts, comparing aerobic, resistance & stretching. All 3 had large & significant effect on pain (not diff from each other); also improves QOL (possibly depression) https://t.co/RYba99OWCh https://t.co/izpHjeXWCt
Dr. John Cush RheumNow ( View Tweet)
EMA has approved Secukinumab for the expanded approvals for use in pediatric patients with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) . Approvals based on the JUNIPERA trial, showing reduced the risk of flare & Dz activity w/ SEC https://t.co/6pWc6nEUd9 https://t.co/gGGyzEEh0u
Links:
Dr. John Cush RheumNow ( View Tweet)
Inferior IL-17 Inhibitor Responses in Psoriatic Women
Pooled data from two large (IXE trials show that male patients had greater clinical responses than did female patients with PsA are largely unexplored. Reasons for this is unexplained.
https://t.co/OAu6gCweDt https://t.co/lsM6hZUwNQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of IV CTX (n 13) vs mepolizumab (n 7)(MPZ; IL-5 inhib) in severe eosinophilic granulomatosis polyangiitis. BVAS & EOS# equal at mo 1 & 6, but MPZ had better retention(61 vs 5%) & less AEs (29% vs 54%) https://t.co/7s38a67C1r https://t.co/oXLb1ctoc7
Links:
Dr. John Cush RheumNow ( View Tweet)
New Updated GRAPPA Psoriatic Arthritis Recommendations
The GRAPPA treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains." A great reference to print & carry.
https://t.co/0K8LP3LA9j https://t.co/1fJlzPKLWl
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA Clinical Review 15 min podcast on treatment of carpal tunnel syndrome and trigger finger and common hand problems in clinical practice; featuring Drs. Mary M. McDermott, and Kelly Currie https://t.co/IhD6iqVyqC https://t.co/aChPLIbuEu
Links:
Dr. John Cush RheumNow ( View Tweet)
The EMA's CHMP has positively recommended upadacitinib for use in Non-radiographic axial spondyloarthritis (nr-axSpA) based on Phase 3 SELECT-AXIS 2 study showing superior ASAS40 responses at week 14 https://t.co/uc7oOKglLX https://t.co/yz7M8U3rkk
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA Patient Page on "What is Carpal Tunnel Syndrome ? A great patient resource, full read with graphics https://t.co/lL9209YpdL https://t.co/28ceu2obma
Links:
Dr. John Cush RheumNow ( View Tweet)
🆕🚨Possible future avenues for myositis therapeutics: DM,IMNM&IBM
Current treatment options in IIM management
1st line:GC+
Skin➡️MTX/AZR/MMF
Muscle➡️AZR/MMF/MTX
Lung➡️AZR/MMF
Dysphagia/Diaphragmatic weakness➡️IVIG
RP-ILD➡️IVIG+CNI+CYC/RTX
Calcinosis➡️JAKi
https://t.co/G3vN055Gyq https://t.co/Qy9MULgeMs
Links:
EnvisionRheumat ERheumat ( View Tweet)
Idiopathic inflammatory myopathies, Camille Rasmussen #BJHM #MedEd #FOAMed #Medtwitter #Myopathy #rheumtwitter #MedStudentTwitter https://t.co/dsqwHIAqnX
Brown Journal of Hospital Medicine BrownJHM ( View Tweet)
Are you an Expert in Still's disease, Periodic Fevers, FMF or Autoinflammatory Dz? We will add you to our expert referral listing. DM me to get on the list! https://t.co/hCkC1Yu9Nh
Dr. John Cush RheumNow ( View Tweet)
Novel Anti-TNF Shines in Rheumatoid Arthritis Trial
A new way of inhibiting tumor necrosis factor (TNF) for treating rheumatoid arthritis showed strong results in a phase II/III clinical trial, researchers said.
https://t.co/fTmWeIrVD5 https://t.co/LPk2Ok2gac
Links:
Dr. John Cush RheumNow ( View Tweet)
Placebo Works Best in Combination
Analysis of two large clinical trial datasets shows that placebo response rates in randomised controlled trials (RCTs) of patients with rheumatoid arthritis are better when the patient continued background MTX.
https://t.co/JmNGRQWv6L https://t.co/77LdcTwCvl
Links:
Dr. John Cush RheumNow ( View Tweet)
New Updated GRAPPA Psoriatic Arthritis Recommendations
The GRAPPA treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains."
https://t.co/PkDofio1eh https://t.co/kp6UEgwonV
Links:
Dr. John Cush RheumNow ( View Tweet)
Video: Post Hoc Analysis of the ORAL Surveillance Study
https://t.co/PVzfYlzdQa https://t.co/0RpA3CfTEE
Links:
Dr. John Cush RheumNow ( View Tweet)
Gabapentin Implicated in Overdose Deaths
Recent FDA and MMWR warnings suggest that gabapentin was present in almost 10% of US overdose deaths between 2019 & 2020. The report also stated that gabapentin was the cause of the death in half of these cases.
https://t.co/ilNAd7ifdZ https://t.co/5GIcySXSDZ
Links:
Dr. John Cush RheumNow ( View Tweet)